| Literature DB >> 30510541 |
Patrick T LaBreck1, Gregory K Rice2,3, Adrian C Paskey1,2, Emad M Elassal4,5, Regina Z Cer2,3, Natasha N Law4,5,6, Carey D Schlett4,5, Jason W Bennett7,8, Eugene V Millar4,5, Michael W Ellis9, Theron Hamilton2, Kimberly A Bishop-Lilly2, D Scott Merrell1,8.
Abstract
Staphylococcus aureus is the leading cause of skin and soft tissue infections (SSTI). Some S. aureus strains harbor plasmids that carry genes that affect resistance to biocides. Among these genes, qacA encodes the QacA Multidrug Efflux Pump that imparts decreased susceptibility to chlorhexidine, a biocide used ubiquitously in healthcare facilities. Furthermore, chlorhexidine has been considered as a S. aureus decolonization strategy in community settings. We previously conducted a chlorhexidine-based SSTI prevention trial among Ft. Benning Army trainees. Analysis of a clinical isolate (C02) from that trial identified a novel qacA-positive plasmid, pC02. Prior characterization of qacA-containing plasmids is limited and conjugative transfer of those plasmids has not been demonstrated. Given the implications of increased biocide resistance, herein we characterized pC02. In silico analysis identified genes typically associated with conjugative plasmids. Moreover, pC02 was efficiently transferred to numerous S. aureus strains and to Staphylococcus epidermidis. We screened additional qacA-positive S. aureus clinical isolates and pC02 was present in 27% of those strains; other unique qacA-harboring plasmids were also identified. Ten strains were subjected to whole genome sequencing. Sequence analysis combined with plasmid screening studies suggest that qacA-containing strains are transmitted among military personnel at Ft. Benning and that strains carrying qacA are associated with SSTIs within this population. The identification of a novel mechanism of qacA conjugative transfer among Staphylococcal strains suggests a possible future increase in the prevalence of antiseptic tolerant bacterial strains, and an increase in the rate of infections in settings where these agents are commonly used.Entities:
Keywords: Staphycoccus aureus; antiseptic; chlorhexedine digluconate; conjugation; plasmid acquisition
Year: 2018 PMID: 30510541 PMCID: PMC6252503 DOI: 10.3389/fmicb.2018.02664
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Bacterial strains used in the study.
| DSM1417 | CI | A 2-58 | 4 | 12-Jul-11 | CHG | CP012119.2 | ST8 | EryR,LvxR,OxaR,Sxts, Clis | (Johnson et al., | ||
| DSM1418 | CI | A 2-58 | 4 | 21-Sep-11 | CHG | CP012120.2 | ST8 | EryR,LvxR,OxaR,SxtS, CliS | (Johnson et al., | ||
| DSM1487 | N | A 2-54 | 2 | 11-Mar-11 | S | Not Sequenced | ST8 | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1488 | N | B 1-19 | 4 | 13-Oct-11 | ES | CP016856.2 | ST72 | EryS,LvxS,OxaS,SxtS, CliS | This study | ||
| DSM1489 | N | F 3-330 | 4 | 26-Jul-10 | S | Not Sequenced | ? | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1490 | N | A 1-50 | 1 | 26-Jul-10 | ES | Not Sequenced | ST8 | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1491 | N | E 3-330 | 2 | 26-Jul-10 | S | CP016855.2 | ST8 | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1493 | CI | B 1-50 | - | 17-Mar-11 | ES | Not Sequenced | ST8 | EryR,LvxR,OxaR,SxtS, CliS | this study | ||
| DSM1494 | CI | A 2-58 | - | 19-Jul-11 | CHG | CP025495.1 | ST8 | EryR,LvxR,OxaR,SxtS, CliS | This study | ||
| DSM1495 | CI | C 2-54 | 3 | 8-Sep-11 | S | CP016858.2 | ST8 | EryR,LvxR,OxaR,SxtS, CliS | This study | ||
| DSM1496 | CI | A 2-54 | 2 | 11-Mar-11 | S | Not Sequenced | ST8 | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1497 | CI | A 2-54 | 2 | 11-Mar-11 | S | MCID00000000.2 | ST8 | EryR,LvxS,OxaR,SxtS, CliS | This study | ||
| DSM1498 | CI | E 2-19 | 3 | 11-Mar-11 | CHG | CP016863.2 | ST8 | EryR,LvxS,OxaR,SxtS, CliS | this study | ||
| DSM1499 | CI | B 1-19 | 4 | 11-Oct-11 | ES | CP017094.2 | ST8 | EryR,LvxS,OxaS,SxtS, CliS | This study | ||
| DSM1500 | CI | B 2-58 | 1 | 29-Oct-10 | CHG | Not Sequenced | ST8 | EryR,LvxR,OxaR,SxtS, CliS | This study | ||
| DSM1501 | N | B 2-58 | 4 | 19-Sep-11 | CHG | Not Sequenced | ST8 | EryR,LvxS,OxaS,SxtS, CliS | This study | ||
| DSM1502 | N | B 2-58 | 4 | 28-Sep-11 | CHG | Not Sequenced | ST8 | EryR,LvxS,OxaS,SxtS, CliS | This study | ||
| DSM1503 | N | C 2-19 | 1 | 1-Sep-11 | CHG | Not Sequenced | ST72 | EryS,LvxS,OxaS,SxtS, CliR | This study | ||
| DSM1504 | N | A 2-58 | 4 | 7-Sep-11 | CHG | CP016861.2 | ST8 | EryR,LvxR,OxaR,SxtS, CliS | This study | ||
| DSM1553 | Large plasmid-cured strain | EryS, CadS, RifR, NovR | NT | This study | |||||||
| DSM1573 | EryS, CadS, RifR, NovR | NT | This study | ||||||||
| DSM1575 | Large plasmid-cured 1625.C01, Cadmium sensitive, Rifampin and Novobiocin resistant | EryS, CadS, RifR, NovR | NT | This study | |||||||
| DSM1581 | Erythromycin sensitive, Rifampin and Novobiocin resistant | EryS, CadR, RifR, NovR | NT | This study | |||||||
| DSM1582 | Cadmium sensitive, Rifampin and Novobiocin resistant | EryS, CadR, RifR, NovR | NT | (Gill et al., | |||||||
| DSM1580 | Erythromycin sensitive, Rifampin and Fusidic acid resistant | EryS, CadR, RifR, FusR | NT | (Dunny et al., | |||||||
| DSM1671 | Transconjugant obtained from 2014.C02 to C02-RN mating | CadR, RifR, NovR | NT | This study | |||||||
| DSM1672 | Transconjugant obtained from 1969.N to C02-RN mating | CadR, RifR, NovR | NT | This study | |||||||
| DSM1673 | Transconjugant obtained from 2014.C02 to 42-RN mating | CadR, RifR, NovR | NT | This study | |||||||
| DSM1674 | Transconjugant obtained from 2014.C02 to | EryR, RifR, NovR | NT | This study | |||||||
RN indicates rifampin novobiocin resistant lab generated strain. RF indicates rifampin and fusidic acid resistant lab generated strain.
CI, Clinical Isolate; N, Nasal colonizing Isolate.
.
CHG, Chlorhexidine. S, Standard. ES, Enhanced Standard. Standard indicates a preventative medical briefing and access to an SSTI clinic. Enhanced standard indicates the standard intervention, an additional shower each week and enhanced SSTI education and surveillance. Chlorhexidine indicates receipt of a bottle of 4% chlorhexidine soap to use for the extra weekly shower in addition to the interventions received in the enhanced standard group.
MLST, Multilocus Sequence Type; ?, Novel sequence type.
.
genes shown to be present in strains by real-time PCR. NT, not tested.
Figure 1Simplified pC02 plasmid map. Regions amplified during the pC02 PCR screen are indicated by gray boxes along the plasmid backbone. Genes of interest are labeled in the gray arrows: cad (cadmium resistance loci), tra (putative conjugation gene) erm (erythromycin resistance loci), qacA (qacA/R loci) rep (replication A). Image drawn to scale.
pC02-based PCR screen.
| 2014.C01 | CHG | – | – | – | – | – | + | – | + | – | – | – | ||
| 2014.C02 | CHG | + | + | + | + | + | + | + | + | + | + | + | ||
| 1960.N02$ | CHG | – | – | – | – | – | – | – | – | – | – | – | ||
| 2148.N$ | ES | – | – | – | – | – | – | – | – | – | – | – | ||
| 1534.C01 | CHG | – | – | – | – | – | + | – | + | – | – | – | ||
| 1625.C01 | CHG | – | – | – | – | – | + | – | + | – | – | – | ||
| 3011.C01 | ES | – | – | – | – | – | + | – | + | – | – | – | ||
| 5107.N | S | – | – | – | – | – | + | – | + | – | – | – | ||
| 5116.N | ES | – | – | – | – | – | + | – | + | – | – | – | ||
| 1624.C01 | S | – | – | – | – | – | + | – | + | – | – | + | ||
| 1626.C01 | S | – | – | – | – | – | + | – | + | – | – | + | ||
| 1626.N | S | – | – | – | – | – | + | – | + | – | – | + | ||
| 1971.C01 | S | – | – | – | – | – | + | – | + | – | – | + | ||
| 1969.N | CHG | + | + | + | + | + | + | + | + | + | + | + | ||
| 3020.C01 | CHG | + | + | + | + | + | + | + | + | + | + | + | ||
| 2075.N02$ | CHG | – | – | – | – | – | + | + | + | – | – | + | ||
| 2116.N02$ | CHG | – | – | – | – | – | + | + | + | – | – | + | ||
| 2148.C01$ | ES | – | – | – | – | – | + | + | + | – | – | + | ||
| 5118.N | S | – | – | – | – | – | + | + | + | – | – | + | ||
$, MSSA isolate.
multiple isolates were obtained from the same patient/numbers in the strain name indicate individual patient designations.
CHG, chlorhexidine; ES, enhanced standard; S, standard.
Number 1–10 indicate the primer sets used for the pC02 screen, qacA is an independent PCR for qacA/B. +, PCR amplification. - no PCR amplification.
CHG, chlorhexidine; MIC, minimum inhibitory concentration.
Group range and median.
Figure 2Chlorhexidine MIC for each plasmid-pattern group. The MIC of chlorhexidine for each strain was determined by broth dilution. All strains were grouped according to the results of the pC02 PCR screen as follows: No amplification, strains that didn't amplify at all with the pC02 primer set; pC01-like, strains that had an amplification pattern that matched the control 2014.C01 isolate (amplification with 6 and 8); pC01+qacA/B, strains that had an amplification pattern that matched 2014.C01 but also amplified with the qacA/B primer set; pC02-like, strains that had an amplification pattern that matched the control 2014.C02 strain; and PP-6,7,8, strains that showed amplification with primer sets 6, 7, 8, and qacA/B. Graphed values represent means from three independent replicates for each strain. Error bars represent the standard deviation of the group mean. Statistically significant differences are indicated as determined by a one-way Anova with correction for multiple comparisons using Tukey's multiple comparison method.
Summary of S. aureus replicons.
| 2,917,985 | pC01a 3,269 | CP025490.1 | N | |
| pC01b 27,043 | CP012118.2 | N | ||
| 2,864,345 | pC02a 3,269 | CP025489.1 | N | |
| pC02 61,539 | CP012121.2 | Y | ||
| 2,877,915 | p1625.C01 27,067 | CP016862.2 | N | |
| 2,871,639 | p1626.C01a 3,269 | CM009343.1 | N | |
| p1626.C01b 27,209 | CM009344.1 | N | ||
| p1626.C01c 43,994 | CM009345.1 | Y | ||
| 2,864,344 | p1969.Na 3,269 | CP025487.1 | N | |
| p1969.Nb 61,505 | CP016860.2 | Y | ||
| 2,873,208 | p1971.C01a 3,269 | CP025486.1 | N | |
| p1971.C01b 21,841 | CP016859.2 | Y | ||
| p1971.C01c 37,941 | CP016857.2 | N | ||
| 2,856,605 | p2148.C01a 3,266 | CP025488.1 | N | |
| p2148.C01b 32,660 | CP017095.2 | Y | ||
| 2,748,803 | p2148.N 3,459 | CP025481.1 | N | |
| 2,865,166 | p3020.C01a 3,269 | CP025496.1 | N | |
| p3020.C01b 61,505 | CP025497.1 | Y | ||
| 2,873,063 | p5118.Na 3,269 | CP025482.1 | N | |
| p5118.Nb 53,799 | CP016854.2 | Y |
Scaffolded assembly in multiple contigs.
Figure 3Dendrogram of MRSA isolates that were subjected to whole genome sequencing and analysis in this study. A multiple sequence alignment (MSA) was created from nucleotide substitutions. A maximum likelihood tree was constructed with S. aureus USA300_TCH1516 as the root from the nucleic acid MSA using PhyML (version 3.2) tree search with the GTR substitution model and 1000 bootstrap replicates. Bootstrap values are shown at the base of the individual nodes.
Identified SNVs in strains that harbored pC02.
| 494641 | Hypothetical protein | Non-synonymous SNV | ||
| 704843 | – | SNV (noncoding) | ||
| 1014474 | Enoyl-ACP reductase | Synonymous SNV | Synonymous SNV | |
| 1014480 | Synonymous SNV | Synonymous SNV | ||
| 1014681 | Ambiguous basecall | Synonymous SNV | ||
| 1014693 | Ambiguous basecall | Synonymous SNV | ||
| 1014699 | Synonymous SNV | |||
| 1014708 | Synonymous SNV | |||
| 1466112 | Thymidylate synthase | Non-synonymous SNV | Non-synonymous SNV | |
| 1466151 | Non-synonymous SNV | Non-synonymous SNV | ||
| 1567680 | Minor structural protein | Non-synonymous SNV | ||
| 2650114 | Lantibiotic ABC transporter ATP-binding protein | Synonymous SNV | Synonymous SNV | |
| 2850131 | - | SNV (noncoding) |
Single nucleotide variations (SNVs) by position (coordinates with respect to the reference genome for methicillin-resistant MRSA USA300_TCH1516; NC_010079.1) for each of the three isolates that were found to be clonal.
Conjugative transfer of pC02.
| C02 | C02-RN | Yes | 7.51E-09 | 6.58E-09 |
| 3020.C01 | C02-RN | Yes | 9.59E-09 | 5.39E-09 |
| 1969.N | C02-RN | Yes | 1.42E-08 | 8.79E-09 |
| C02 | 42-RN | Yes | 8.20E-09 | 9.15E-09 |
| 3020.C01 | 42-RN | Yes | 3.25E-09 | 3.98E-09 |
| 1969.N | 42-RN | Yes | 1.87E-09 | 5.83E-10 |
| C02 | 1625-RN | Yes | 1.29E-08 | 7.19E-09 |
| 3020.C01 | 1625-RN | Yes | 3.95E-08 | 2.95E-08 |
| 1969.N | 1625-RN | Yes | 2.46E-09 | 1.91E-09 |
| C02 | Yes | 6.82E-09 | 3.65E-09 | |
| C02 | Yes | 7.25E-11 | 1.77E-10 | |
| C02 | Not observed | ND in 2.29E10 | NA | |
| 1626.N | C02-RN | Not observed | ND in 1.26E10 | NA |
| 5118.N | C02-RN | Not observed | ND in 1.14E10 | NA |
| 1971.C01 | C02-RN | Not observed | ND in 1.10E10 | NA |
ND, not detected in indicated number of examined recipient CFU.
NA, not applicable.
Figure 4Chlorhexidine MIC for transconjugant strains. The MIC to chlorhexidine for each indicated strain was determined by broth dilution. (A) C02-RN TC is a transconjugant obtained from mating C02 with C02-RN. C02-RN TC2 is a transconjugant obtained from mating 1969.N with C02-RN. 42-RN TC is a transconjugant obtained from mating C02 with 42-RN. 42-RN and C02-RN are pC02-free recipient cells. (B) Epi-RN TC is a transconjugant obtained from mating C02 with S. capitis RN. Epi-RN is pC02-free recipient S. capitis RN. Graphed values represent three independent replicates for each strain and the bar indicates the mean. Statistically significant differences are indicated as determined by a Student's t test; a correction for multiple comparisons using the Holm-Sidak's method was applied for C02-RN, C02-RN TC and C02-RN TC2.